Abstract
Background. Cardiovascular disease (CVD) is the leading cause of death among chronic kidney disease (CKD) patients. Vascular calcification is highly prevalent in this population and is an independent predictor of cardiovascular mortality. Vascular calcification in uraemic patients is known to be an active and regulated process subject to the action of many promoting and inhibitory factors. The role of vitamin D in this process remains controversial. We evaluated the relationship between serum levels of 25-hydroxyvitamin D (25(OH)D) and vascular calcification evaluated by plain X-ray images, in predialysis patients with CKD stages 4 and 5.
Methods. We performed a cross-sectional study with 210 CKD patients stages 4 and 5 managed at our predialysis unit. Patients were 63.5 ± 13 years of age, 60.5% males, 64.8% diabetics and 47.1% with a history of CVD. Plain X-ray images of pelvis, hands and lateral lumbar spine from all subjects were studied for calculation of semiquantitative vascular calcification scores as described by Adragao and Kauppila. Results. We found a high prevalence of vascular calcification in our population. Adragao scores revealed only 47 patients (22.4%) without vascular calcification and 120 (57.1%) with scores higher than 3. Kauppila scores revealed only 29 patients (13.8%) without aortic calcifications and 114 patients (54.3%) with scores higher than 7. Higher vascular calcification scores were related to older age, diabetes, history of CVD and lower levels of 25(OH)D. Only 18.5% of patients had adequate levels of 25(OH)D (>30 ng/mL), 53.7% of them had insufficient levels (15-30 ng/mL) and 27.8% had deficient levels
Introduction
Cardiovascular mortality is the leading cause of death among patients with chronic kidney disease (CKD) [1] . Recently, there has been growing interest in the role that vascular calcifications play in the development of cardiovascular disease (CVD) in these patients [2] . There are two main types of vascular calcification, intimal and medial calcification. Intimal calcification is primarily related to calcification of the atherosclerotic plaque and leads to progressive occlusion of the vessel lumen. Medial calcification, also known as Monckeberg's medial sclerosis, increases arterial wall stiffness and reduces vascular distensibility, thus increasing pulse pressure; this contributes to the development of CVD. Both types of calcification develop earlier and more intensely in CKD patients than in the general population [3, 4] . It is well known that deposition of calcium and phosphate on the vascular walls is not merely a passive process driven by serum concentrations higher than the saturation point but an active and regulated process that involves phenotypic transformation of vascular smooth muscle cells into osteoblast-like cells and is subject to the action of promoting and inhibitory factors [5] . The role of vitamin D in this process is controversial. High doses have been reported to cause hypercalcaemia and soft tissue calcification. On this basis, it has been proposed that generalized use of calcium-based phosphate binders and high doses of vitamin D analogues to control secondary hyperparathyroidism may contribute to vascular calcification in CKD patients [6] . However, vitamin D deficiency has been reported to increase cardiovascular morbidity and mortality both in the general population and in CKD patients [7, 8] . The effects of vitamin D on vascular calcification appear to follow a biphasic pattern, with both excess and deficiency promoting its development [9] .
The objectives of this study were to evaluate the occurrence of vascular calcification in predialysis patients with CKD stages 4 and 5 by plain X-ray examination of hands, pelvis and lateral spine and to analyse the possible associations with serum levels of 25(OH)D and other known vascular risk factors.
Materials and methods
This was an observational cross-sectional study conducted on a cohort of non-dialysis patients with CKD stages 4 and 5, who were followed in the predialysis unit of our centre during 2008 and 2009. The protocol of this study was in accordance with the Declaration of Helsinki 1975, as revised in 2000.
Patients
A total of 210 patients were included with a mean age of 63.5 ± 13 years (21-91); 60.5% of them were male and 64.8% were diabetic; and the mean glomerular filtration rate estimated by Modification of Diet in Renal Disease (MDRD-4) formula was 20.7 ± 5 (86.5% were stage 4 and 13.5% were stage 5). We reviewed patients' medical records for their history of CVD, defined as previous documented events of coronary disease, stroke or peripheral vascular disease. For the purpose of this study, we considered that coronary disease included acute myocardial infarction, coronary events confirmed by coronary catheterization and coronary revascularization procedures; stroke included ischaemic or haemorrhagic stroke; and peripheral vascular disease included any treatment by the angiology unit for ischaemic lesions of the lower limbs, amputation of lower limbs or intermittent claudication. We found a total of 47.1% patients with a history of CVD (23.8% with coronary disease, 16.7% with stroke and 27.6% with peripheral vascular disease).
Vascular calcifications
Vascular calcifications were evaluated by plain X-ray using semiquantitative scores as described by Adragao et al. [10] and Kauppila et al. [11] . To calculate the Adragao simple vascular calcification score (SVCS), anteroposterior plain X-ray images of pelvis and hands were taken for each patient. We divided the X-ray images of hands horizontally into two sections by tracing an imaginary line over the upper limit of the metacarpal bones and searched each section for vascular calcifications-either with a linear or an irregular pattern-in the radial and digital arteries. We divided the X-ray image of the pelvis into four sections by tracing an imaginary vertical line over the spine axis and an imaginary horizontal line over both femoral heads. We then searched each section for calcifications in the iliac and femoral arteries. Each section was assigned a score: 0 for absence and 1 for presence of vascular calcifications. Thus, a total of eight sections (two from each hand and four from the pelvis) were examined and scored for each patient. The total score of a patient was calculated as the addition of the partial scores and ranged from 0 to 8. As reported in previous studies, SVCS scores >3 are associated with an increase in the rate of CVD [12] .
To calculate the Kauppila index, a lateral lumbar spine X-ray image was taken for each patient. A semiquantitative scoring system was used to assess the calcifications in the anterior and posterior aortic walls as observed in the four image segments corresponding to the areas in front of each of the first four lumbar vertebrae. Each segment was assigned a score for anterior wall calcifications and a score for posterior wall calcifications. Scores ranged between 0 and 3 (0 = no calcification, 1 = irregular punctate calcifications, 2 = localized linear calcifications, 3 = linear calcifications spanning the length of the vertebra). The total score of a patient was calculated as the addition of the partial scores and ranged from 0 to 24. Kauppila scores >7 have been associated with higher coronary calcification as evaluated by electron beam computed tomography-a technique with high sensitivity and specificity [13] . All X-ray images were evaluated by the same expert radiologist, who was blinded to the patients' clinical and laboratory data.
Laboratory analysis
Serum levels of 25-hydroxyvitamin D 2 + D 3 were measured by chemiluminescent immunoassay (LIAISON ® 25 OH Vitamin D TOTAL Assay, DiaSorin Inc.) for all patients. On the basis of other published studies, we considered vitamin D deficiency for serum 25(OH)D levels lower than 15 ng/mL, vitamin D insufficiency for levels between 15 and 30 ng/mL and adequate level of vitamin D for serum levels higher than 30 ng/mL [14] .
Routine laboratory tests consisted of complete blood count, glomerular filtration rate calculated by the MDRD-4 formula and serum biochemistry including assessment of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, uric acid, albumin, calcium, phosphorus, intact parathyroid hormone (iPTH) measured by electrochemiluminescence assay 'Beckman', 24-h proteinuria, homocysteine, CRP and lipoprotein A.
Statistical analysis
Statistical analysis was performed with the SPSS software 17.0 (SPSS Inc., Chicago, IL, USA). Results of the continuous variables were expressed as mean ± SD; categorical variables were expressed as frequencies. For univariate analysis, we used the unpaired Student's t-test, Mann-Whitney U-test or Chi-squared test depending on the characteristics of the variables. Multivariate analysis consisted in a stepwise binary logistic regression between SVCS >3 or ≤3 and those variables that were significant in a univariate analysis: age, diabetes, history of CVD, 25(OH)D, haemoglobin, albumin and homocysteine levels. Binary logistic regression was performed between Kauppila scores >7 and <7 as dependent variables and age, diabetes, history of CVD, LDL 
Results
SVCS yielded 47 patients (22.4%) without and 163 (77.6%) patients with vascular calcification; within the latter group, 120 patients (57.1%) had SVCS >3. Kauppila score showed complete absence of aortic calcifications for only 29 patients (13.8%) and was >7 for 114 patients (54.3%). Table 1 shows the differences in epidemiological, clinical and laboratory results between patients with SVCS > 3 and ≤ 3. As it can be observed, patients with higher calcification scores were older and had a higher prevalence of diabetes and history of CVD, higher levels of homocysteine and lower levels of haemoglobin, albumin and 25(OH)D. Table 2 compares the epidemiological, clinical and laboratory results of patients with Kauppila scores >7 and ≤7. It can be observed that the variables associated with higher calcification scores were age, prevalence of diabetes, history of CVD, high triglycerides and homocysteine levels, low levels of LDL cholesterol and low levels of 25(OH)D. We found no difference between groups, in the proportion of patients treated with vitamin D analogues or calcium-based phosphate binders.
Mean 25(OH)D serum level was 21.6 ± 10 ng/mL. Only 18.5% of patients had adequate levels, while 53.7% had insufficient levels and 27.8% had deficient levels. An analysis with the Spearman's correlation coefficient revealed inverse correlations between 25(OH)D serum levels and both calcification scores (SVCS: Spearman = − 0.346, P < 0.005; Kauppila: Spearman= −0.245, P < 0.005). Table 3 shows the relationship between 25(OH)D levels and vascular calcification as estimated with the SVCS and Kauppila scores.
In multivariate analysis, independent predictors of SVCS > 3 are age (P = 0.002), diabetes (P = 0.0001), CVD (P = 0.007) and low 25(OH)D levels (P = 0.02). Independent predictors of Kauppila score >7 are age (P = 0.0001), CVD (P = 0.011) and low 25(OH)D levels (P = 0.017) ( Table 4) . Tables 1 and 2 show that 20% of patients were under treatment with vitamin D analogues. After excluding those patients, an equivalent analysis to that performed with the whole group yielded similar results: univariate analysis comparing patients with SVCS > or ≤ 3 yielded significance for age, diabetes, history of CVD (acute myocardial infarction and peripheral vascular disease), low levels of LDL cholesterol, lower albumin levels and low levels of 25(OH)D. Comparison of patients with Kauppila scores > or ≤ 7 yielded significance for age, diabetes, CVD (coronary disease and peripheral vascular disease) low LDL cholesterol, high triglycerides and low 25(OH)D. In multivariate analysis, independent predictors of SVCS >3 are diabetes (P = 0.0001), CVD (P = 0.002) and low 25(OH)D levels (P = 0.025). Independent predictors of Kauppila score >7 are age (P = 0.0001), high triglycerides levels (P = 0.033) and low 25(OH)D levels (P = 0.04).
Discussion
In this study, high prevalence of arterial calcifications in predialysis patients with CKD stages 4 and 5 was observed. A number of studies have demonstrated high prevalence of arterial calcifications in patients who were on dialysis, as well as an association between such calcifications and cardiovascular mortality [16, 17] . Studies with predialysis patients have also demonstrated high prevalence of vascular calcifications by using quantitative methods [18] [19] [20] . Similar to the results of our study, the process of vascular calcification has been found to start early, before the initiation of dialysis.
The presence of calcifications has been evaluated by different methods: ultrasonography, electron beam computed tomography, multislice computed tomography or plain Xray [21] [22] [23] . These methods vary in sensitivity and specificity as well as in their capacity to differentiate the type of calcification. We used semiquantitative assessment with plain X-ray. Although this approach might be relatively crude and does not allow for differentiation between intimal and medial calcification, it has the advantages of being simple, cheap and applicable in daily clinical practice. Furthermore, it has been validated in several studies that established the relationship of arterial calcification with increased stiffness and reduced compliance of arterial walls and that confirmed its direct relationship with allcause and cardiovascular mortality in dialysis patients [12, 24, 25] . In our study, the analysed clinical and epidemiological variables revealed an association between vascular calcifications and age, diabetes and history of CVD. This finding is in agreement with other published studies, where calcifications are generally related to age, diabetes, race, arterial hypertension, time on dialysis and CVD [26] . It should be noted that our population has a very high prevalence of diabetes (68.7%), which may contribute, at least in part, to the high prevalence of vascular calcifications observed.
It has been known for some time that the process of vascular calcification is not merely a passive process of calcium and phosphate deposition due to serum supersaturation of these minerals. It is actually an active and regulated process, involving several genes and proteins of bone mineral metabolism and resulting in phenotypical transformation of vascular smooth muscle cells into osteoblast-like cells, subject to the action of many promoting and inhibitory factors [27] .
Elevated serum phosphate is one of the main factors promoting vascular calcification in uraemic patients. Several in vitro and in vivo studies suggested that elevated phosphate levels may initiate calcification [28] . Such an effect may be mediated by a phosphate-stimulated cellular methylation process that leads to the expression of Cbfa1, a stimulating factor of the differentiation of mesenchymal cells into osteoblasts [29] . However, there is no consensus in the literature about the effect of other bone mineral metabolism alterations on vascular calcifications. While some studies report that high calcium and iPTH levels promote calcification, other studies have failed to confirm these findings [30, 31] . In this study, no relationship was found between phosphate, calcium and iPTH levels and the presence of vascular calcifications. Such a relationship would probably be more evident in dialysis patients. However, serum phosphate levels in our population were within the normal range, according to the KDI-GO guidelines, and the use of phosphate-binding drugs was rather low. Actually, we found that patients with higher vascular calcification scores had slightly higher serum phosphate levels, although the differences did not reach statistical significance, possibly due to our reduced sample size.
The role of vitamin D in the development of vascular calcification is still controversial. Experimental studies have demonstrated that suprapharmacological doses of vitamin D can produce histological changes in the arterial walls, including calcification [32, 33] . Although humans are seldom exposed to such toxic doses, the recently observed high prevalence of vascular calcifications in CKD patients who are on dialysis triggered an alarm about the risk that widespread use of vitamin D analogues to treat secondary hyperparathyroidism, together with calcium salts as phosphate binders, has contributed to the development of calcification by increasing serum levels of the Ca × P product [30, [34] [35] [36] . We found that our patients already showed a higher prevalence of calcification before dialysis. Furthermore, only 9% of them were using calcium-containing phosphate binders; in this regard, no difference was found between patients with and without calcifications. Regarding the use of vitamin D analogues, only 20% of patients in this study were under treatment with these drugs, mostly administered in low doses (calcitriol 1.25 mcg/week or paricalcitol 3 mcg/week) and for a short period of time, since administration started during follow-up in the predialysis unit, and patients were included in this study during the first 3 months of follow-up in this unit. Finally, no differences were found between patients with or without vascular calcifications in terms of proportion of patients treated with calciumbased phosphate binders or vitamin D analogues nor in the prescribed doses. Thus, in this study, the use of calcium-based phosphate binders or vitamin D analogues appeared to be irrelevant in the development of vascular calcification.
Studies have suggested that some of the physiological effects of vitamin D may include inhibitory actions on arterial calcification. Both the endothelial and smooth muscle cells of the vascular wall have local 1-α-hydroxylase activity and vitamin D receptors, whose activation at this level causes anti-inflammatory, antiproliferative and antifibrotic effects through reduced expression of cytokines and metalloproteinases-which would promote calcification-and through increased expression of inhibitory factors of calcification [37, 38] . Low levels of 25(OH)D are known to be associated with hypertension, left ventricular hypertrophy and increased cardiovascular morbidity and mortality in both the general and the CKD population [39] [40] [41] [42] [43] [44] . Vitamin D deficiency could lead to calcification and consequently to increased stiffness and impaired compliance of arterial walls, all of which could partially account for its clinical effects on cardiovascular morbidity and mortality [45] [46] [47] . Our study seems to support this view, since we found a significant association between 25(OH)D deficiency and insufficiency and both vascular calcification scores, which was independent of age or diabetes. We observed a higher prevalence of low 25(OH)D levels, despite that fact that patients were from the southern regions of the Island of Gran Canaria, one of the European areas with the highest average number of sunlight hours throughout the year.
Regarding treatment with natural vitamin D or active vitamin D metabolites, there is no definitive clinical evidence of their potential benefits in preventing CVD. Recent clinical observations suggested that vitamin D analogues provide a survival benefit for patients with CKD independent of the serum levels of calcium, phosphate and PTH [48, 49] . A retrospective analysis of renal patients treated with either calcitriol or paricalcitol showed that paricalcitol treatment was associated with better survival [50] . This finding is in agreement with experimental results, which showed that calcitriol induced calcification of vascular smooth muscle cells while paricalcitol did not [6] . Recent observations revealed that CKD is associated with a high prevalence of 25(OH)D deficiency or insufficiency, already from early stages of the disease, and that it could be related to CVD. It has been recommended that therapy with the natural form of vitamin D (ergocalciferol or cholecalciferol) should be initiated if 25(OH)D levels fall below 30 ng/mL [51] . However, the beneficial effect of such an approach needs to be confirmed by clinical trials currently underway [52, 53] .
We are aware of the limitations of this study. Being a cross-sectional study, the associations described here should be interpreted with caution and do not imply a pathophysiological relationship of causality. It could be argued that vitamin D may be simply a marker of patients who are older, diabetic or with a more severe history of CVD. Furthermore, the relatively reduced number of patients included in this study could account for our failure to find associations that have been previously described in the literature, e.g. between calcification and serum phosphate levels. Larger-scale longitudinal multicentre studies are needed to confirm our results and to evaluate the possible outcome of treatments with native vitamin D. We propose that, given the high prevalence of vascular calcification in advanced stages of CKD, such a treatment should be considered in earlier stages.
